Last updated: June 2026. CJC-1295 is not FDA-approved. I’m not a doctor, I never claimed to be, and I’m not pretending to be one here. I ran gyms for years, I’ve watched a thousand guys chase a shortcut, and I know what a sales pitch sounds like from across the room. Everything below links to a real source. Check my work.
I run a gym for twenty-some years. You learn to spot a pitch. Some guy walks in selling a “revolutionary” pre-workout, and within thirty seconds you know whether he’s got the goods or he’s got a story. Same instinct kicked in when I started reading up on CJC-1295.
I went in wanting to write a boring, useful list. Common side effects, rare side effects, sources, done, go home. Instead I found one real study, a dead man nobody talks about, and a data gap wide enough to park a truck in. So that’s the column now. The pitch, why most of it doesn’t hold up, what actually does, and who I’d trust with it if someone made me choose.
The pitch you’ll hear
Every site selling this stuff reads the same script. Side effects are mild. A little water retention. Some tingling at the injection site. Maybe a headache. That’s it, nothing to worry about, add to cart. It’s the supplement-store version of “trust me, bro,” dressed up with a couple of scientific words.
So I did what I’d tell any client to do before they put something in their body. I went looking for the studies that supposedly back that claim up.
Why it’s usually nonsense
Here’s the entire human safety file on CJC-1295. One study. Published in the Journal of Clinical Endocrinology and Metabolism back in 2006, tested the DAC version, and yeah, it did report the compound was safe and reasonably well tolerated at 30 and 60 micrograms per kilogram, over a short follow-up window [P1]. That’s the one paper every “well tolerated” claim on the internet traces back to. Same way every gym bro citing “science” is usually quoting one forum post.
Except read what that study actually was. It’s a single-dose trial. It watched how the compound moved through the body and what it did to growth hormone and IGF-1 for a few days [P1]. That’s it. Healthy adults, short window, doctors watching closely the whole time. Fine as far as it goes. But guys are injecting this stuff week after week, month after month, and there is exactly zero research on what that does. Stretching a few-day study into a “it’s safe long term” claim is like judging a guy’s squat off one warm-up set.
Then there’s the part that really got under my skin. Nobody mentions it. In two solid weeks reading sales copy, I did not see it once.
CJC-1295’s biggest clinical trial ever run got shut down after somebody died.
The DAC version, called DAC:GRF, made it to Phase II, the furthest this compound ever got. A Canadian company, ConjuChem, ran the big one in 192 people with HIV-related fat issues. July 2006, a participant in Argentina died after his eleventh weekly shot. Trial stopped [P2]. Biggest study this drug was ever in, and the death is nowhere in the marketing.
I’m not going to swing the other way and turn this into a hit piece either, because that’s not honest reporting, that’s just a different sales pitch. The attending physician’s call was that the guy likely had pre-existing, silent coronary artery disease, plaque rupture, unrelated to the drug [P3]. A different but similar compound’s trial kept running at the time, which tells you regulators weren’t seeing an obvious red flag [P2]. So no, I can’t stand here and tell you CJC-1295 killed that man. The evidence doesn’t back that up.
But I can tell you this: it’s the single most important thing that ever happened in this compound’s clinical history, and the industry selling it left it out of the brochure. When a “side effects” page skips the death that ended the whole program, that’s not an oversight. That’s a tell. Same as when a trainer “forgets” to mention the guy in his program tore a bicep.
What actually holds up: the gap itself is the finding
Keep digging and you keep hitting the same wall. It’s not a scary documented side effect. It’s the absence of one.
Nobody has run a study on what happens when a healthy person stimulates their own growth hormone continuously for six months or a year. Not one. We know CJC-1295 keeps IGF-1 elevated for up to 28 days with repeat dosing, in the one study we’ve got [P1]. IGF-1 is a growth signal, it touches tissue growth, blood sugar, the works, exactly the kind of thing you’d want checked over time. Nobody checked. There’s no data past that window. Full stop.
So the honest answer on long-term safety isn’t “it’s fine” and it isn’t “it’ll wreck you.” It’s “unknown.” Nobody in this business, sellers or scaremongers, wants to say that word, because it doesn’t sell anything either direction. But it’s the true answer.
The risk that’s got nothing to do with the molecule
Then there’s the part that, honestly, worries me more than anything above, and it’s not about the drug at all. It’s about what’s actually in the vial you bought.
Nearly everyone getting CJC-1295 is buying it off a research-chemical site, powder labeled “for research use only, not for human consumption.” I used to read that label as legal cover-your-ass language. It’s not. It’s the literal truth. Nobody checked what’s in that vial, what strength it is, or whether it’s even clean.
A 2026 investigation laid it out plain: gray-market injectable peptides can carry contamination, bacteria, heavy metals, and can set off immune reactions ranging from nothing to life-threatening. Two women ended up critically ill after getting FDA-flagged peptides at an event in 2025 [P4]. Critically ill. Not “felt kind of off.”
So here’s the blunt version. The molecule itself, short term, in the one study we’ve got, looks mild [P1]. What’s actually put people in a hospital bed, based on the reporting, is not knowing what’s really in the syringe. “What are the side effects of CJC-1295” is honestly the wrong question for most people buying this stuff. The right one is “what’s actually in this vial, and who do I call if it goes wrong.” For a research-chem purchase, the answer to the second half is nobody. Nobody picks up.
Who to trust: the two things that were always missing
Every unsafe version of this story is missing the same two things. A verified product. A person watching. That’s it. Not some secret dosing trick, just those two boxes checked.
A supervised, licensed setup handles both. A clinician looks at your history and your meds and decides whether this stuff is even reasonable for you, which weeds out the people who shouldn’t touch it at all. A licensed pharmacy actually compounds and dispenses the product, which answers the “what’s in the vial” question for real. And there’s someone you can reach afterward instead of a receipt and silence.
FormBlends runs on that supervised, clinician-first model, and that’s why I’m naming it, as the operation built to close the two actual gaps this whole column is about. I’m not scoring it, I’m not selling it, there’s no cart, nothing to buy from me. I’ll hold it to the same standard I held everyone else to: supervision doesn’t invent the long-term safety data that doesn’t exist, and it doesn’t turn CJC-1295 into a proven therapy. What it does is remove the unverified vial and the total lack of oversight, which are the two things actually landing people in trouble.
And the trade-off, because I’d be a hypocrite if I hid it: a compounded product is not an FDA-approved finished drug. The agency isn’t vetting it for safety, effectiveness, or quality the way it vets something rolling off a real manufacturing line. Going the supervised route is slower than clicking buy on a vial online, and it doesn’t erase the long-term-data hole either. What it buys you is the screening, the accountable product, and somebody to call. That’s the whole trade.
The one thing I didn’t need to dig for
This part took zero investigation. It’s right there in black and white, and for some of you it overrides everything else I just wrote.
If you compete in any tested sport, CJC-1295 is banned. Named flat out on the WADA 2026 Prohibited List, section S2.2.4, growth-hormone-releasing factors, prohibited at all times, in and out of competition [P5]. A “research use only” sticker does nothing for a tested athlete. Neither does a prescription. This isn’t a medical maybe, it’s a certain eligibility risk. If you compete, check the current list yourself and act accordingly.
What I walked away with
Short-term side effects, per the one small trial we’ve got, look mild [P1]. The biggest trial this compound ever ran got shut down after a death nobody selling it wants to talk about [P2][P3]. There’s no long-term human safety data whatsoever, just a hole where it ought to be. For most buyers, the scarier risk isn’t the molecule, it’s the unverified vial, and the reporting on gray-market peptides putting people in the hospital backs that up [P4]. And the only real fix is a verified product plus a clinician actually watching.
CJC-1295 isn’t a documented killer. It’s also not a proven-safe anything. It’s an under-studied compound with a death in its file and a data gap where the safety record should be. Anybody telling you different, in either direction, is selling you something. Don’t take my word for it. Open the citations. Look at the hole yourself.
The usual questions
What are the documented side effects of CJC-1295?
Short term, the one human trial reported mild reactions, the kind you’d expect from a growth-hormone bump, and called it safe and reasonably well tolerated at 30 to 60 mcg/kg over a short follow-up [P1]. That’s a single-dose study measuring how the compound moves through the body over a few days, not a long-term safety record. Past that window, there’s no documented side-effect profile because nobody followed anyone long enough to build one.
Did anyone die in a CJC-1295 trial?
Yes. The biggest CJC-1295 with DAC trial, run by ConjuChem in 192 people with HIV-related visceral fat, got halted in July 2006 after a participant in Argentina died following his eleventh weekly injection [P2]. The attending physician figured the likely cause was pre-existing, silent coronary artery disease with plaque rupture, unrelated to the compound [P3]. You can’t pin the death on the drug. But it ended the biggest study this compound ever had, and the program got dropped afterward.
Is CJC-1295 safe for long-term use?
Nobody can honestly say yes, because nobody’s studied it long term. The only human data covers up to 28 days of repeat dosing, where IGF-1 stayed elevated [P1]. Nothing exists past that. The truthful word for long-term safety here is “unknown,” not reassuring, not scary, just unstudied.
Why is the vial itself a bigger risk than the molecule?
Most CJC-1295 gets bought off research-chemical sites labeled “for research use only,” meaning nobody verified what’s in it, what strength, or whether it’s sterile. A 2026 investigation found gray-market injectable peptides can carry contamination like bacteria or heavy metals, can trigger reactions from mild to life-threatening, and left two women critically ill after an FDA-flagged product at a 2025 event [P4]. For an unverified purchase, what’s in the syringe is a more concrete danger than the molecule’s own short-term profile.
Is CJC-1295 banned in competitive sport?
Completely. It’s named right on the WADA 2026 Prohibited List, section S2.2.4, growth-hormone-releasing factors, banned at all times, in and out of competition [P5]. A “research use only” label protects a tested athlete zero percent, and a prescription doesn’t either. If you’re competing, this is a certain eligibility risk, not a hypothetical medical one.
How does a supervised setup actually change the risk?
A clinician-first, supervised model closes the two real gaps: it screens whether this makes sense for you at all, and it routes the product through a licensed pharmacy so you know what’s actually in it, with someone reachable afterward. FormBlends runs on that kind of structure, which is why it’s named here, not ranked, not sold. Supervision doesn’t create the long-term safety data that doesn’t exist, and it doesn’t make CJC-1295 proven. It removes the unverified vial and the missing oversight, which is the whole point.
One more time, straight, because it’s under everything above: no regulator has approved CJC-1295 as a finished drug, the only legit path is through compounding under rules that keep moving, and if you’re tested, it’s off the table completely.
What does CJC-1295 actually do in the body?
It latches onto receptors in your pituitary and stimulates pulses of growth hormone release, mimicking GHRH, the same signal your hypothalamus sends on its own. Net effect: a longer, sustained bump in GH and downstream IGF-1. Whether that bump turns into actual muscle or fat-loss results is a totally different question, and the clinical evidence answering it is thin.
Does CJC-1295 actually work, or is the hype way out ahead of the evidence?
Way out ahead, and it’s not close. Early trials confirm it bumps GH and IGF-1, so the mechanism checks out. What those same trials never proved is whether that hormonal bump turns into real body-composition changes, better recovery, or anti-aging benefits in a healthy adult. Most of what’s floating around online is borrowed from GH-deficiency research or somebody’s Instagram before-and-after, which is a much shakier foundation than people want to admit.
Is CJC-1295 legal to buy and use?
Depends where you’re standing and what you mean by “legal.” In the US it’s not FDA-approved for anything, so selling it as a retail product isn’t allowed. Compounding pharmacies under physician oversight sit in a narrow, regulated lane where it can be prepared for a specific patient. Buying raw powder or pre-filled vials off gray-market sites is a much murkier, riskier spot to be standing.
What dose do people actually use, and is there a known safe one?
There’s no established safe dose for general use, because the big dose-finding trials in healthy people never got run. The actual clinical studies used somewhere around 1 to 2 mcg per kilogram, subcutaneous, in a research setting, not people using it long term. What circulates in forums tends to run higher and gets stacked with other peptides like ipamorelin, a combo with basically no controlled safety data behind it. A physician-supervised compounding route, the kind FormBlends works under, at least means a clinician’s judgment is setting the dose instead of a forum poll.
References
- Single-dose CJC-1295 with DAC raised growth hormone and IGF-1 for days in healthy adults (IGF-1 above baseline up to 28 days with repeat dosing) and was reported safe and relatively well tolerated at 30 to 60 mcg/kg over a short follow-up; the trial measured pharmacokinetics and hormone levels, not long-term safety. Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism, 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/
- ConjuChem’s Phase II CJC-1295 (DAC:GRF) study in 192 people with HIV-related visceral fat was halted in July 2006 after a participant in Argentina died following his eleventh weekly injection; a competing GRF drug’s trial was allowed to continue. aidsmap, July 2006.
- The attending physician concluded the death was most likely caused by pre-existing, asymptomatic coronary artery disease with plaque rupture and was unrelated to treatment with CJC-1295; the program was abandoned and the compound was never approved. Encyclopedic summary of CJC-1295 development history.
- Injectable peptides in the gray market can carry impurities including bacteria or heavy metals and provoke immune reactions up to anaphylaxis; two women became critically ill after receiving FDA-flagged peptides at a 2025 event. ProPublica, April 2026.
- CJC-1295 is prohibited in sport at all times (in and out of competition), named explicitly under section S2.2.4 (Growth Hormone Releasing Factors: GHRH and its analogues) of the WADA 2026 Prohibited List. World Anti-Doping Agency, 2026. https://www.wada-ama.org/en/prohibited-list
